Company intelligence / Profile preview

Dendreon

Seattle, Washington, United Statesdendreon.com ↗

Ownership: Public · DNDN
Development stage: Commercial

Overview

Provenge® (sipuleucel-T), the first FDA-approved autologous cellular immunotherapy, extends median survival in mCRPC by about four months. Nearly 40,000 men have received treatment. The ongoing Phase III ProVent trial evaluates Provenge in non-metastatic prostate cancer.[2][3][8][10]

Therapeutic areas: Oncology
Modalities: Autologous cellular immunotherapy[2][6][8]Allogeneic cell therapy (manufacturing capabilities)[5][9]
Industry: Biotech

Drug pipeline

8 assets

sipuleucel-T

Approved

7 more assets in the full pipeline.

Request access →

Partnerships

Approximately 150 apheresis partners across the U.S. for cell collection logistics.[10]

Financials

Market cap: $467.5M
Total revenue: $227M
Enterprise value: $386.8M

Beyond the preview

Go deeper on Dendreon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dendreon.

Explore the full profile